This federal Project Grant award of $362,415 from the National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), supports research to investigate the role of the orexin neurotransmitter system in regulating intraocular pressure (IOP) and its potential implications for glaucoma treatment. The research aims to: 1) examine the influence of the brainstem raphe pallidus on IOP elevations induced by stimulation of the dorsomedial hypothalamus/perifornical region, 2) assess the...
This federal Project Grant award of $715,098 from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) aims to enhance glaucoma risk prediction through advanced genomics and machine learning. The key products and services to be delivered include: Improving polygenic risk score (PRS) performance for glaucoma by leveraging natural language processing techniques and electronic health record data from over 68,000 patients to extract refined glaucoma phenotypes. The...
This federal Project Grant award, totaling $496,633, was awarded by the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867). The grant supports a research project at Duke University to investigate the role of glypicans, specifically glypican-4 (GPC4), in trabecular meshwork function, intraocular pressure regulation, and the development of glaucoma. The project aims to uncover the molecular mechanisms by which augmented GPC4 expression and secretion may dysregulate Wnt...
This Project Grant award from the National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), provides $234,000.00 to Oregon Health & Science University (OHSU) to research restoring intraocular pressure (IOP) homeostatic function in glaucomatous eyes. The project aims to use senolytic treatments and senoreversion therapies, either alone or in combination with stem cell transplantation, to address IOP dysregulation and vision loss associated with glaucoma. The award...
The National Eye Institute (NEI) awarded a $448,250 Project Grant under the Vision Research federal grant program (CFDA 93.867) to The Research Foundation For The State University Of New York, doing business as Upstate Medical Center, for a project titled "Composition and Function of Optix-Cofactor Transcription Complexes in the Eye". The project aims to characterize the Optix transcription factor complexes and their specific roles in Drosophila eye development, with the goal of...
This $435,659 Project Grant award from the National Eye Institute (NEI) under the Vision Research (CFDA 93.867) program supports research at the University of California, San Francisco (UCSF) to study the stability of collagen IV, a key structural component of the extracellular matrix and basement membranes. The goal is to develop genetic or chemical approaches to stabilize collagen IV assembly, which could lead to new treatments for Gould syndrome and other collagen-associated disorders that...
This Project Grant award, with a total funding amount of $661,635.00, was provided by the National Eye Institute (NEI) under the federal Vision Research grant program (CFDA 93.867). The primary objective of the research project is to elucidate the molecular changes in the extracellular matrix of the outflow pathway that regulate outflow facility in steroid-induced ocular hypertension and open-angle glaucoma. The research aims to determine if the same extracellular matrix changes lead to...
The National Eye Institute (NEI), under the Department of Health and Human Services, has awarded a $568,122 Project Grant (CFDA 93.867 - Vision Research) to Baylor College of Medicine. The grant, effective from July 1, 2025, through March 31, 2030, aims to confirm the contribution of the neurovascular unit (NVU) to the pathogenesis of glaucoma and identify endothelial cell-specific ligands with potential for neuroprotective therapy. The key objectives of this project are to: 1) globally map...
The National Eye Institute (NEI) awarded a $813,213 Project Grant (CFDA 93.867 - Vision Research) to the Icahn School of Medicine at Mount Sinai to conduct a multiomic analysis of preclinical biomarkers for primary open-angle glaucoma (POAG). The 5-year research project will analyze proteomic and metabolomic profiles in plasma samples from a matched case-control group nested within prospective health studies, along with genetic and clinical data, to better understand POAG pathophysiology and...
This $201,825 Project Grant award from the National Eye Institute (NEI) Vision Research program (CFDA 93.867) supports research to evaluate the use of condensin inhibitors as a potential topical treatment for Pseudomonas aeruginosa bacterial eye infections. The lead investigator, Dr. Valentin Rybenkov at the University of Oklahoma, will collaborate with Dr. Michelle Callegan at the University of Oklahoma Health Sciences Center to conduct in vivo studies examining the toxicity, corneal...
This $218,068 Project Grant awarded by the National Eye Institute (NEI) under CFDA Program 93.867 "Vision Research" aims to structurally and biochemically characterize wild-type lysyl oxidase-like 1 (LOXL1) protein and variants associated with pseudoexfoliation glaucoma (XFG). The project will examine how specific LOXL1 variants impact the protein's structure, processing, interactions, and catalytic activity to further understanding of how LOXL1 contributes to XFG, the most common form of secondary open-angle glaucoma. The 3-year project will be conducted by the Georgia Tech Research Corp, a non-profit research organization and state institution of higher education, with the goal of laying groundwork for future therapeutic development for XFG.